Home

Jonathan Poole

CIK 1604689 · CFO · last filed 2026-06-01

Jonathan Poole is a CFO who has filed 14 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing, for ACAD, was dated Jun 1, 2026. Across all open-market trades the lifetime net is −$271.5K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $55.9K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$55.9K

Companies

3

Total Filings

14

Lifetime Open-Market Net

-$271.5K

Filer Profile

Reported Address
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO, CA 92130
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACAD Director 2,010 $27.81 $55.9K $0 2 2026-06-01
Evelo Biosciences, Inc. (EVLO) Delisted CFO — $0.00 — $0 3 2020-01-30
GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Chief Financial Officer 4,906 $0.00 $3 -$271.5K 9 2018-02-12

Recent Filings

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-01 ACAD Mixed +2,010 $0 EDGAR
2026-03-20 ACAD Grant (A) — $0 EDGAR
2020-01-30 Evelo Biosciences, Inc. (EVLO) Delisted Grant (A) — $0 EDGAR
2019-01-16 Evelo Biosciences, Inc. (EVLO) Delisted Grant (A) — $0 EDGAR
2018-05-10 Evelo Biosciences, Inc. (EVLO) Delisted Grant (A) — $0 EDGAR
2018-02-12 GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Grant (A) — $0 EDGAR
2017-07-24 GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Mixed — -$130.9K EDGAR
2017-05-10 GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Mixed +22,034 -$61.9K EDGAR
2017-03-01 GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Grant (A) — $0 EDGAR
2016-11-09 GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Buy (P) +7,000 $23.4K EDGAR
Showing 1–10 of 14
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.